Literature DB >> 10888308

Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.

H Matsuo1, A Matsui, R Nasu, H Takanaga, N Inoue, F Hattori, H Ohtani, Y Sawada.   

Abstract

PURPOSE: We present a case report of propiverine-induced Parkinsonism. We previously reported the induction of catalepsy by amiodarone, aprindine and procaine, which possess a diethylaminomethyl moiety and demonstrated selective blockade of dopamine D2 receptors by these drugs in mice. We hypothesized that drugs possessing a diethylaminomethyl structure may generally induce Parkinsonism and/or catalepsy.
METHODS: Thus, we performed a study to examine whether oxybutynin, pentoxyverine and etafenone, as well as propiverine, induce catalepsy in mice.
RESULTS: The intensity of drug-induced catalepsy was in the order: haloperidol > etafenone > pentoxyverine > propiverine > oxybutynin. In vivo occupancy of dopamine D1, D2 and mACh receptors in the striatum was also examined. The in vitro binding affinities to the D1, D2 and mACh receptors in the striatum synaptic membrane were within the ranges of 2.4-140 microM, 380-4,200 nM, and 1.2-2,800 nM, respectively.
CONCLUSIONS: These results support the idea that any drug possessing a diethylaminomethyl moiety may contribute to the induction of catalepsy, possibly by occupying dopamine receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888308     DOI: 10.1023/a:1007516916077

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  29 in total

1.  Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency.

Authors:  Y Sasaki; K Hamada; C Yamazaki; T Seto; Y Kimura; Y Ukai; Y Yoshikuni; K Kimura
Journal:  Int J Urol       Date:  1997-07       Impact factor: 3.369

2.  Aminoalkynyldithianes. A new class of calcium channel blockers.

Authors:  T C Adams; A C Dupont; J P Carter; J F Kachur; M E Guzewska; W J Rzeszotarski; S G Farmer; L Noronha-Blob; C Kaiser
Journal:  J Med Chem       Date:  1991-05       Impact factor: 7.446

3.  Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies.

Authors:  K Haraguchi; K Ito; H Kotaki; Y Sawada; T Iga
Journal:  Drug Metab Dispos       Date:  1997-06       Impact factor: 3.922

4.  Transitory procaine-induced Parkinsonism.

Authors:  F Gjerris
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-02       Impact factor: 10.154

5.  Characterization of palytoxin-induced catecholamine secretion from cultured bovine adrenal chromaffin cells. Effects of Na(+)- and Ca(2+)-channel blockers.

Authors:  M Yoshizumi; A Nakanishi; H Houchi; K Morita; I Katoh; M Oka
Journal:  Biochem Pharmacol       Date:  1991-06-21       Impact factor: 5.858

6.  Drug-induced parkinsonism: a growing list.

Authors:  J F Martí Massó; N Carrera; M Urtasun
Journal:  Mov Disord       Date:  1993       Impact factor: 10.338

7.  A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism.

Authors:  A Negrotti; S Calzetti
Journal:  Mov Disord       Date:  1997-01       Impact factor: 10.338

8.  Effects of propantheline bromide on basal growth hormone, cortisol and prolactin levels.

Authors:  B M Davis; A A Mathé; R C Mohs; M I Levy; K L Davis
Journal:  Psychoneuroendocrinology       Date:  1983       Impact factor: 4.905

9.  Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan.

Authors:  R L Binder; H Kazamatsuri; T Nishimura; D E McNiel
Journal:  Am J Psychiatry       Date:  1987-11       Impact factor: 18.112

10.  Parkinsonism, tardive dyskinesia, akathisia, and depression induced by flunarizine.

Authors:  C Chouza; A Scaramelli; J L Caamaño; O De Medina; R Aljanati; S Romero
Journal:  Lancet       Date:  1986-06-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.